ANGO - AngioDynamics, Inc.
| Previous Close | 22.43 |
| Open | 22.58 |
| Bid | 22.30 x 800 |
| Ask | 23.11 x 1100 |
| Day's Range | 22.47 - 23.02 |
| 52 Week Range | 15.26 - 24.49 |
| Volume | 228,190 |
| Avg. Volume | 195,436 |
| Market Cap | 854.156M |
| Beta (3Y Monthly) | 0.82 |
| PE Ratio (TTM) | 49.36 |
| EPS (TTM) | 0.47 |
| Earnings Date | Mar 27, 2019 - Apr 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.00 |
- Zacks•17 hours ago
Allscripts (MDRX) Q4 Earnings Lag Estimates, Bookings Up Y/Y
Significant year-over-year rise in bookings favors Allscripts' (MDRX) fourth-quarter 2018 results.
- Zacks•17 hours ago
Integer Holdings' (ITGR) Q4 Earnings Beat, '19 View Strong
Integer Holdings (ITGR) gains from the core Medical Sales segment's impressive performance in fourth-quarter 2018.
- Zacks•19 hours ago
NuVasive (NUVA) Q4 Earnings Beat Estimates, Margins Fall
NuVasive (NUVA) reports growth in revenues across all key operating segments in the fourth quarter of 2018.
- Zacks•2 days ago
Genomic Health (GHDX) Q4 Earnings Beat Estimates, Margins Up
Genomic Health's (GHDX) year-over-year rise in revenues, driven by a solid uptick in the United States and internationally, makes us optimistic about the stock.
- Zacks•3 days ago
CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up
CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition holds immense promise.
- Zacks•3 days ago
Henry Schein's (HSIC) Q4 Earnings Top, Revenues Lag Estimates
Strength in Henry Schein's (HSIC) global Medical and Technology and Value-added Services businesses in Q4 is encouraging.
- Zacks•4 days ago
Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down
Medtronic (MDT) demonstrates improved performances at CER based on growth in most of the business segments and all geographies.
- Zacks•4 days ago
Ecolab (ECL) Earnings and Revenues Match Estimates in Q4
Ecolab (ECL) sees solid segmental gains in Q4.
- Zacks•5 days ago
Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4
Cryolife (CRY) revenues increase year over year across all geographies and major segments.
- Zacks•8 days ago
Quidel (QDEL) Q4 Earnings and Revenues Surpass Estimates
Quidel's (QDEL) flagship Triage sees strong growth in China in Q4.
- Zacks•9 days ago
Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down
In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.
- Zacks•9 days ago
Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines
Bio-Techne (TECH) sees increase in revenues across key segments.
- Zacks•9 days ago
DaVita (DVA) Q4 Earnings Beat and Revenues Miss Estimates
DaVita's (DVA) Q4 results gain from increasing dialysis services in and outside the United States.
- Zacks•11 days ago
STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates
STERIS (STE) continues to gain from strength in all business segments in Q3.
- Zacks•10 days ago
Medidata (MDSO) Q4 Earnings Beat, Revenues Miss Estimates
Medidata (MDSO) gains from solid segmental performance in Q4.
- Zacks•11 days ago
Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong
Bruker (BRKR) witnesses a sturdy organic revenue uptick riding on the strength of Bruker Scientific Instruments (BSI) and BEST segments.
- Zacks•12 days ago
IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up
IRADIMED (IRMD) reports growth across all operating segments and geographies
- Zacks•15 days ago
Phirbo (PAHC) Q2 Earnings Lag Estimates, Operating Margin Up
Phirbo (PAHC) witnesses significant growth in core segment revenues in Q2.
- Zacks•15 days ago
Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss
Omnicell (OMCL) steadily benefits from product introductions, strategic alliances and digital conversions.
- Zacks•16 days ago
LabCorp's (LH) Q4 Earnings and Revenues Surpass Estimates
LabCorp's (LH) Q4 earnings gain on strength in the Covance Drug Development business.
- Zacks•16 days ago
Cardinal Health (CAH) Beats on Q2 Earnings, Ups FY19 View
Cardinal Health's (CAH) Q2 results benefit from strong sales in the Pharmaceutical segment. An upbeat guidance is indicative of brighter prospects.
- Zacks•16 days ago
Haemonetics (HAE) Earnings Top, Revenues Lag Estimates in Q3
Haemonetics' (HAE) year-over-year earnings growth in Q3 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
- Zacks•16 days ago
Boston Scientific (BSX) Beats on Q4 Earnings, Margins Dip
Boston Scientific (BSX) is leaving no stone unturned to strengthen its core businesses and invest in global markets, which accounted for the uptick in sales across all geographies.
- Zacks•17 days ago
Myriad Genetics (MYGN) Q2 Earnings & Revenues Miss Estimates
Myriad Genetics (MYGN) Q2 performance by Hereditary Cancer testing is encouraging while GeneSight test revenues disappoint.
- Zacks•17 days ago
Cerner (CERN) Q4 Earnings Meet Estimates, Revenues Miss
Cerner (CERN) gains from solid segmental revenues in fourth-quarter 2018. However, the company's 2019 guidance disappoints.
